Orion Reaches All-Time High – Blockbuster Nubeqa Drives Profit Surge
Reading Time: 3 minutes
Orion is a Finnish pharmaceutical company that develops its own medications and also earns income from partner marketing and royalties on key products. Nubeqa is currently the most important driver of growth: Revenue reported by Orion increased by 69% in the second quarter, and annual revenue of over 1 billion Euros is possible by the end of the decade. In addition to increasing profits, Orion is expanding its pipeline: A further potential cancer therapy candidate, ODM-212, is already in clinical development. The stock of the Finnish pharmaceutical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
